Ideas
AI is a boom, not a bubble
AI is not a bubble but an ongoing boom. As AI adoption moves from about 10% of a large addressable market toward 20-30%, it could generate trillion-dollar revenue and cost-saving opportunities, supporting continued investment.
U.S. equities remain robust on earnings power
Although investors have sought to diversify away from the U.S., U.S. companies' earnings power, profitability, innovation and creativity remain ahead. Even if the Fed cuts less than priced, capex and midterm-election-related loose monetary and fiscal policies point to a pretty robust U.S. equity market.
Goldman, Morgan Stanley may turn bank narrative
Goldman Sachs and Morgan Stanley are shaped differently from other banks, with large investment-banking and trading exposures that are expected to perform well, including IB growth above 20% and strong equities trading. If any banks can reverse the weak market reaction to bank earnings, it will be these two.
Chinese EVs may get tariff relief
Chinese producers make the cheapest and most efficient EVs, so if Canada's domestic green agenda takes precedence and EV security concerns are weighed differently, Canadian tariffs on Chinese EVs could soften, creating a potential catalyst for Chinese EV makers.
U.S. actions reinforce dollar's petrodollar role
A key underappreciated aspect of U.S. actions in Venezuela and Iran is the effort to preserve the dollar's central role in global oil payments and the petrodollar system. Even if Canada supplied more oil to China, it would not be priced or transacted in yuan, reinforcing the dollar's importance in global trade and finance.
Luxury demand recovering, especially from China
Richemont's record sales and signs that China is coming back are good news for the luxury sector after a slow period and tough comparisons. The luxury recovery may be gaining traction, though cost pressures and revived competing brands remain risks.
Richemont sales strong, margin risks remain
Richemont delivered record sales as jewelry outperformed handbags and China showed signs of recovery, but gold costs and adverse currency moves are weighing on profitability. The key investor question is whether jewelry-led outperformance can continue as other luxury brands revive with new designers.
Novo faces generic semaglutide competition pain
Semaglutide patent expirations in Canada, China, India, Brazil and other countries open the market to dozens of generic drugmakers and could push prices as low as $5 a month in some countries. Novo Nordisk is most exposed because it is its product going off patent and it is already struggling to keep up with Eli Lilly.
Eli Lilly has obesity-market upper hand
Eli Lilly has gained the upper hand in the obesity-drug market as Novo Nordisk struggled with supply and was slower to enter some markets; with Novo facing patent expiry and generic competition, Lilly is well positioned in the fast-growing obesity-drug space.
This Bloomberg Markets video, published January 15, 2026,
features Kokou Agbo-Bloua, Charlie Wells, Diana Choyleva, Andrea, Alyssa McDonald
discussing AI-SECTOR, SPY, GS, MS, Chinese EVs, UUP, Luxury sector, Richemont, NVO, LLY.
9 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Kokou Agbo-Bloua,
Charlie Wells,
Diana Choyleva,
Andrea,
Alyssa McDonald
· Tickers:
AI-SECTOR,
SPY,
GS,
MS,
Chinese EVs,
UUP,
Luxury sector,
Richemont,
NVO,
LLY